Protagenic Therapeutics, Inc.
PTIX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 3.50 | -0.30 | 0.80 | -2.63 |
| FCF Yield | -12.54% | -6.40% | -2.06% | -0.98% |
| EV / EBITDA | -5.80 | -13.10 | -28.34 | -68.99 |
| Quality | ||||
| ROIC | -562.70% | -123.41% | -49.00% | -40.35% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.76 | 0.74 | 0.56 | 0.62 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | – |
| Free Cash Flow Growth | -9.42% | -93.10% | 28.69% | -107.49% |
| Safety | ||||
| Net Debt / EBITDA | 0.34 | 0.29 | -0.04 | 0.05 |
| Interest Coverage | 0.00 | -42.04 | -25.88 | -8.33 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -747.35 | -1,472.03 | -1,891,746.33 | 0.00 |